Re-irradiation of High Grade Gliomas: a Quality of Life Study
NCT01711580, Withdrawn, Maastricht Radiation Oncology
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Re-irradiation of High Grade Gliomas: a Quality of Life Study | ClinicalTrials.gov |
| NCT number | NCT01711580 | ClinicalTrials.gov |
| Status | Withdrawn | ClinicalTrials.gov |
| Enrollment | 0 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Maastricht Radiation Oncology | ClinicalTrials.gov |
| Conditions | Anaplastic Astrocytoma, Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | ClinicalTrials.gov |
| Interventions | EORTC QLQ-C30, EORTC QLQ-BN20, Hopkins Verbal Learning Test-Revised (HVLT-R), Stroop color-word test, Controlled oral word association test (COWA), Jamar hand dynamometer, EORTC QLQ- FA13, Trail Making Test (TMT) | ClinicalTrials.gov |
| First posted | 2012-10-22 | ClinicalTrials.gov |
| Last updated | 2015-05-12 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline in the palliative effect of re-irradiation in patients with a high grade glioma, defined by quality-of-life parameters | baseline, 6-8weeks, 12 weeks, 18-20 weeks, 30-32 weeks | These Quality of life parameters include: * The change in the EORTC QLQ-C30 score from baseline to endpoint * The change in the EORTC QLQ-BN20 score from baseline to endpoint * The change in the EORTC QLQ-FA13 score from baseline to endpoint * The change in cognition from baseline to endpoint as measured by the HVLT-R, the TMT, the Stroop-test and the COWA * The change in grip strength from baseline to endpoint | ClinicalTrials.gov |
| Secondary | Overall survival of patients with glioblastoma and anaplastic glioma after re-irradiation | 6 months after the last patient is included | \- Months from the start of re-irradiation to death | ClinicalTrials.gov |
| Secondary | Progression free survival of patients with glioblastoma and anaplastic glioma after re-irradiation | 6 months after the last patient is included | \- Months from the start of re-irradiation to tumorprogression | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 22
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 1202204 | BACKGROUND | PubMed |
| 7725125 | BACKGROUND | PubMed |
| 8277801 | BACKGROUND | PubMed |
| 8434241 | BACKGROUND | PubMed |
| 8993101 | BACKGROUND | PubMed |
| 9440735 | BACKGROUND | PubMed |
| 10030252 | BACKGROUND | PubMed |
| 10613305 | BACKGROUND | PubMed |
| 11325440 | BACKGROUND | PubMed |
| 12913103 | BACKGROUND | PubMed |
| 14701778 | BACKGROUND | PubMed |
| 15758009 | BACKGROUND | PubMed |
| 15817019 | BACKGROUND | PubMed |
| 16447036 | BACKGROUND | PubMed |
| 16875833 | BACKGROUND | PubMed |
| 17031558 | BACKGROUND | PubMed |
| 17509812 | BACKGROUND | PubMed |
| 18425939 | BACKGROUND | PubMed |
| 21324954 | BACKGROUND | PubMed |
| 21520004 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)